Navigation Links
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
Date:5/25/2011

f gout patients are considered to be under-excretors of uric acid, and recent studies have shown that defects in renal transporters have been genetically linked to gout.  Consequently, increasing renal excretion of uric acid by moderating URAT1 transporter activity may provide the most physiologically appropriate treatment for gout.  In addition, because increasing the excretion of serum uric acid is additive to the effects of drugs that decrease the production of uric acid, such as allopurinol and febuxostat, lesinurad in combination with such drugs has the potential to treat the significant portion of the gout population that is not adequately treated with existing therapies.

Lesinurad has been evaluated as a single agent and in combination with the approved xanthine oxidase inhibitors, allopurinol and febuxostat.  Over 500 people have received lesinurad in Phase 1 and 2 clinical trials.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad, our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 (RDEA119), is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combinatio
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "Investment Analysis of the ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the US medical device sector identifies the key ... venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... 22, 2014 Cyberonics, Inc. (NASDAQ: CYBX ... and management of epilepsy, today announced it will participate in ... Wednesday, January 14, 2015, in San Francisco ... Chief Executive Officer, will speak at 11:00 AM Pacific Time.  ... by clicking on the Investor Relations link on the Cyberonics ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
... China, May 3, 2011 /PRNewswire-Asia/ -- Winner Medical ... Medical") a leading manufacturer of medical dressings, medical ... PurCotton® products in China, today reported that its ... the 13th China International Mother-Infant-Child Products Fair ("MICF") ...
... 3, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... "OND") of the U.S. Food and Drug Administration (the "FDA") ... its appeal, the reviews of the New Drug Application (the ... of the March 22, 2010 Oncology Drugs Advisory Committee meeting ...
Cached Medicine Technology:Winner Medical Exhibited its PurCotton Retail Products at MICF 2011 in Beijing 2Winner Medical Exhibited its PurCotton Retail Products at MICF 2011 in Beijing 3Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 2Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 3Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 4Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 5
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... December 25, 2014 BambooFlooringChina.com sells many ... quality bamboo flooring. Today, the company announces big ... many styles and colors. , BambooFlooringChina.com is the world’s ... the promotion is valid until Jan. 20, 2015. , ... and woven with a natural thread. All the bamboo ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... Pharmaceuticals,Corp. (NASDAQ: NCST ; TSX: NCS) announced today ... Finance & Administration and Chief Financial,Officer in order to ... to any of NUCRYST,s businesses, effective April 15, 2008. ... "On behalf of the Board, I want to ...
... Toronto Stock Exchange Symbol: CYT ... ... the,global leader in cryotherapy products to treat cardiac arrhythmias, today,announced that ... (AFib) was presented at the 74th Annual Meeting,of the German Cardiac ...
... Medical Records Institute (MRI),announces a new TEPR Award ... announced at the TEPR 2008 opening session,on Monday, ... new TEPR Award is the first major effort ... meet a range of EMR medicolegal,requirements, including identity ...
... Effects of maltreatment can damage a child for a lifetime, ... estimated 91,000 babies in the United States were victims of ... 29,181 infants who suffered abuse or neglect during their first ... report -- the first national examination of the risk for ...
... 2008 Integrated,Pharmaceuticals, Inc. (OTC Bulletin Board: INTP) ... more than six hundred retail outlets,including thirty schools ... has agreed to carry the new mineral enhanced ... carry this new and unique beverage. It,addresses a ...
... childhood cancer survivors living in the United States, researchers ... treatment that can occur years after therapy, called late ... Georgetown University Hospital, a team of oncologists, nurses, social ... survivorship manual, tailored for each child treated for cancer. ...
Cached Medicine News:Health News:NUCRYST Announces Senior Management Change 2Health News:NUCRYST Announces Senior Management Change 3Health News:CryoCath Reports Data Presented at the 74th Annual Meeting of the German Cardiac Society 2Health News:CryoCath Reports Data Presented at the 74th Annual Meeting of the German Cardiac Society 3Health News:Medical Records Institute Announces New TEPR Award for EMRs Best Meeting Medicolegal Requirements 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3Health News:Snack Brothers Distributors to Sell New HEALTHYCAL+ Bottled Water 2Health News:Lombardi Comprehensive Cancer Center publishes manual for childhood cancer survivors 2Health News:Lombardi Comprehensive Cancer Center publishes manual for childhood cancer survivors 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: